Paolo Tarantino: Final OS from BROCADE3 phase 3 trial

Paolo Tarantino, Medical Oncologist, Research Fellow at Dana-Farber Cancer Institute, shared a post on X/Twitter:

“Final OS from BROCADE3 phase 3 trial: adding veliparib to 1L carbo-taxol did not improve OS in BRCA-mutant patients with advanced TNBC. Notably, mPFS (>12 months) and mOS (≃30 months) were longer than expected. Effect of the carbo-taxol combo, or chance?”

Visit the article website.
Source: Paolo Tarantino/X